• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Viridian Therapeutics Inc (NQ: VRDN )

    12.93 +0.66 (+5.38%)
    Streaming Delayed Price Updated: 11:56 AM EDT, Jul 11, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 753,266
    Open 12.66
    Bid (Size) 12.92 (1)
    Ask (Size) 12.94 (4)
    Prev. Close 12.27
    Today's Range 12.50 - 13.10
    52wk Range 10.93 - 24.18
    Shares Outstanding 9,587,155
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    3 Small-Cap Stocks With Explosive 2X Growth Potential
    Discover three top high-growth small-cap stocks, fueled by potential rate cuts and promising prospects in the second half of 2024. 
    Via InvestorPlace
    Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Viridian Therapeutics, Inc.
    Via Business Wire

    Performance

    YTD
    -42.15%
    -42.15%
    1 Month
    +5.81%
    +5.81%
    3 Month
    -19.74%
    -19.74%
    6 Month
    -45.72%
    -45.72%
    1 Year
    -36.93%
    -36.93%

    More News

    Read More
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease
    From Viridian Therapeutics, Inc.
    Via Business Wire
    7 Analysts Assess Viridian Therapeutics: What You Need To Know
    Via Benzinga
    Unveiling 4 Analyst Insights On Viridian Therapeutics
    Via Benzinga
    Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Viridian Therapeutics, Inc.
    Via Business Wire
    Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences
    From Viridian Therapeutics, Inc.
    Via Business Wire
    Viridian Therapeutics to Participate in Upcoming May Investor Conferences
    From Viridian Therapeutics, Inc.
    Via Business Wire
    VRDN Stock Earnings: Viridian Therapeutics Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Navigating 6 Analyst Ratings For Viridian Therapeutics
    Via Benzinga
    Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results
    From Viridian Therapeutics, Inc.
    Via Business Wire
    Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Viridian Therapeutics, Inc.
    Via Business Wire
    Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024
    From Viridian Therapeutics, Inc.
    Via Business Wire
    Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Viridian Therapeutics, Inc.
    Via Business Wire
    Finding the Next Big Winners: 3 Stocks You Can Snag for Under $20
    Via InvestorPlace
    Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Viridian Therapeutics, Inc.
    Via Business Wire
    Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
    From Viridian Therapeutics, Inc.
    Via Business Wire
    Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
    From Viridian Therapeutics, Inc.
    Via Business Wire
    Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer
    From Viridian Therapeutics, Inc.
    Via Business Wire
    Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Viridian Therapeutics, Inc.
    Via Business Wire
    Here's Why Viridian Therapeutics (VRDN) Stock Is Moving
    Via Benzinga
    Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock
    From Viridian Therapeutics, Inc.
    Via Business Wire
    Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
    From Viridian Therapeutics, Inc.
    Via Business Wire
    Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference
    From Viridian Therapeutics, Inc.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.